Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 16/20 | 0.80 |
| ▸ | MAPK12 | P53778 | 16/20 | 0.80 |
| ▸ | MAPK11 | Q15759 | 16/20 | 0.80 |
| ▸ | MAPK14 | Q16539 | 16/20 | 0.80 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5633659 | 0.89 | MAPK13 (1.00) | MAPK13MAPK12MAPK11MAPK14NPC1 | |
| SCHEMBL5634298 | 0.88 | MAPK13 (0.63) | MAPK13MAPK12MAPK11MAPK14NPC1 | |
| SCHEMBL5634660 | 0.83 | MAPK13 (0.77) | MAPK13MAPK12MAPK11MAPK14KMT2A | |
| SCHEMBL5634827 | 0.83 | MAPK13 (0.77) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL5634392 | 0.83 | MAPK13 (0.76) | MAPK13MAPK12MAPK11MAPK14NPC1 | |
| SCHEMBL5633296 | 0.83 | MAPK13 (0.80) | MAPK13MAPK12MAPK11MAPK14NPC1 | |
| SCHEMBL5634606 | 0.82 | MAPK13 (0.77) | MAPK13MAPK12MAPK11MAPK14KMT2A | |
| SCHEMBL5635104 | 0.81 | MAPK13 (0.72) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL5633786 | 0.81 | MAPK13 (0.72) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL5634079 | 0.80 | MAPK13 (0.67) | MAPK13MAPK12MAPK11MAPK14KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7253197-B2 | Aminothiazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | disclosed |
| EP-1539722-A1 | THIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-15 | — | — | EP | disclosed |
| US-20040038990-A1 | Aminothiazole derivatives | HOFFMANN-LA ROCHE INC. | 2004-02-26 | — | — | US | disclosed |
| WO-2004014884-A1 | THIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038990-A1 | Aminothiazole derivatives | FABP4, GPR119, ABAT | MAPK13 3018/4885MAPK12 2608/4885MAPK11 2347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.